Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data [0.03%]
新型干扰素β-1a治疗多发性硬化症的药房福利预测：使用管理式护理索赔数据制定一线决策工具以进行药房预算规划
Christina M Meyer,Robert Phipps,Deborah Cooper et al.
Christina M Meyer et al.
Objective: To estimate the incremental change in pharmacy per-member-permonth (PMPM) costs, according to various formulary designs, for a new interferon beta-1a product (IB1a2) using administrative claims data. ...
Industry's perception of presenting pharmacoeconomic models to managed care organizations [0.03%]
制药企业向健康管理组织提交药理经济模型的行业认知状况
Bridget M Olson,Edward P Armstrong,Amy J Grizzle et al.
Bridget M Olson et al.
Background: Previous research has shown that pharmacoeconomic (PE) data are considered important but may not be optimally utilized by decision makers. No research has compared the effectiveness of different types of PE mo...
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy [0.03%]
绝经后预防治疗的年度费用模型：雷洛昔芬、阿仑膦酸盐或雌孕激素疗法
C Daniel Mullins,Robert L Ohsfeldt
C Daniel Mullins
Objective: To estimate the annual cost and outcome impacts attributable to raloxifene, alendronate, and estrogen-progestin therapy as prevention therapies among postmenopausal women over the first 7 years of hormone repla...
Shetal S Desai,Babette S Duncan,Alice S Sloan
Shetal S Desai
Objective: To measure the differences in direct health care costs and resource utilization among female enrollees in a health maintenance organization who were aged 45 through 65 years and had either osteoporosis or an os...
Indicators of preventable drug-related morbidity in older adults 2. Use within a managed care organization [0.03%]
指标研究：药物所致可预防疾病在老年人中的发病率观测（二）管理式医疗组织内的用药情况
Neil J Mackinnon,Charles D Hepler
Neil J Mackinnon
Objective: To determine the incidence of preventable drug-related morbidity (PDRM) in older adults in a provider-sponsored network and identify risk factors for PDRM. ...
Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease [0.03%]
三层药品福利设计对慢性病患者购药行为的影响分析
Kavita V Nair,Pamela Wolfe,Robert J Valuck et al.
Kavita V Nair et al.
Objective: To evaluate the impact of 3-tier (copayment) pharmacy benefit structures on medication utilization behavior. Methods: A pret...
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy [0.03%]
非霍奇金淋巴瘤化疗患者预防性使用菲利格拉刺激粒细胞减少发热的天数研究
Shane D Scott,Elizabeth A Chrischilles,Brian K Link et al.
Shane D Scott et al.
Background: Filgrastim prophylaxis lessens the occurrence of febrile neutropenia in patients with non-Hodgkin.s lymphoma (NHL) treated with chemotherapy, but differences in days of therapy and mode (primary or secondary) ...
Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor [0.03%]
通过最佳使用集落刺激因子最大化化疗癌症患者的疗效
John W Mucenski,Jeffrey E Shogan
John W Mucenski
Objective: To discuss clinical data on the utility of 2 colony-stimulating factors (CSFs), filgrastim and pegfilgrastim, in reducing the risk and incidence of neutropenic complications with chemotherapy. ...
Assessing resource use in oncology patients: a comparison of analyses based on claims data and medical chart review [0.03%]
基于理赔数据和病例资料分析的肿瘤患者资源消耗评价方法比较研究
Georgette N Semroc,Jonothan C Tierce,Moshe Fridman
Georgette N Semroc
Background: Provider claims data are used to make medical analyses and decisions, but such databases typically lack important clinical information. Object...